RNA compared with SENS: revenue, margins and what each company keeps, and the suppliers and customers both name

RNAAtrium Therapeutics, Inc.

Mkt capRevenueRevenue

SENSSenseonics Holdings, Inc.

Mkt capRevenueRevenue

Compare

RNAAtrium Therapeutics, Inc.

SENSSenseonics Holdings, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

RNA2 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26—▲+4.14%—

Q1 FY26±3.0%▼−0.30%×0.10

SENS1 of 4 reports

1 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±11.6%▲+36.31%×3.13

= impliedRNA realized, solidSENS realized, hatchedOne scale, both sides: full bar = 37%× = |realized| ÷ impliedSource: market data

RNAAtrium Therapeutics, Inc.

8.56· pre 8.56· delayed

Mkt cap$141.5MRevenue$3MQ2 FY26Revenue—

SENSSenseonics Holdings, Inc.

8.97· pre 9.09· delayed

Pre-marketNov 2 '26delayed

Mkt cap$474.8MRevenue$14MQ2 FY26Revenue$35MFY25

Compare

Pre-marketNov 2 '26delayed

RNAAtrium Therapeutics, Inc.

SENSSenseonics Holdings, Inc.

8.56pre 8.56delayed

Price

8.97pre 9.09delayed

$141.5M

Mkt cap

$474.8M

Q2 FY26$3M

Revenue

$14MQ2 FY26

—

Revenue

$35MFY25

RNA8.56vsSENS8.97Pre-marketNov 2 '26delayed